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Angiotensin II receptor antagonist ameliorates renal
tubulointerstitial fibrosis caused by unilateral ureteral obstruction
SHIGETO ISHIDOYA, JEREMIAH MORRISSEY, RUTH MCCRACKEN, ALVARO REYES, and SAULO KLAHR
Renal Division, Department of Medicine and the Department of Cell Biology and Physiology, Washington University School of Medicine and The Jewish
Hospital of St. Louis, St. Louis, Missouri, USA
Angiotensin II receptor antagonist ameliorates renal tubulointerstitial
fibrosis caused by unilateral ureteral obstruction. Unilateral ureteral
obstruction (UUO) results in tubulointerstitial fibrosis of the obstructed
kidney (OBK). In this study we report that a specific angiotensin II (Ang
II) receptor antagonist, SC-51316, ameliorates the expansion of the renal
cortical interstitium in the OBK of the rat at five days of UUO. This is
similar to the effect of an angiotensin converting enzyme (ACE) inhibitor,
enalapril. SC-51316 (20 mg/liter in the drinking water) or enalapril (200
mg/liter in the drinking water) was administered beginning 24 hours
before UUO and continued through five days after UUO. The relative
volume of the tubulointerstitium (Vv) was measured by a point-counting
method, and monocyte/macrophage infiltration, alpha smooth muscle
actin (aSMA), proliferating cell nuclear antigen (PCNA), and collagen
type IV (collagen IV) protein deposition were examined histologically
using specific antibodies. We also examined the mRNA levels of trans-
forming growth factor j31 (TGF-I31) and collagen IV by reverse transcrip-
tion polymerase chain reaction. In untreated rats with UUO, Vv was
remarkably expanded; collagen IV and aSMA protein deposition in the
interstitium and PCNA labeling of nuclei were increased. These changes
were significantly ameliorated by administration of an ACE inhibitor or an
Ang II receptor antagonist. A monocyte/rnacrophage infiltration was
evident in the OBK of untreated or Ang II receptor antagonist treated rats
but was greatly reduced in the OBK of rats given enalapril. Increased
expression of TGF-f31 mRNA and collagen IV mRNA was blunted (40 to
75%) by the administration of Ang II receptor antagonist or enalapril. The
Ang II receptor antagonist or the ACE inhibitor did not affect the
contralateral kidney of rats with UUO or the control kidney of normal
rats. This study indicates that the renin-angiotensin system has a major
role in the pathogenesis of the tubulointerstitial fibrosis of obstructive
nephropathy. The tubulointerstitial fibrosis of obstructive nephropathy is
most likely mediated by an increased level of Ang II in renal tissue.
Interstitial fibrosis is a major histological finding in kidney
diseases of diverse etiology [1]. Chronic unilateral ureteral ob-
struction (UUO) is a well established model of experimental renal
injury [2, 31. UUO results in changes in renal hemodynamics [2,
3], infiltration of the kidney by macrophages [41, and subsequently
fibrosis of the tubulointerstitium [5].
Angiotensin converting enzyme (ACE) inhibitors have been
shown to have a beneficial effect in several experimental models of
renal disease including cyclosporine A nephropathy [6], puromy-
cm aminonucleoside nephrosis (PAN) [7], and obstructive ne-
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phropathy [5]. Besides directly decreasing angiotensin II (Ang II)
generation, ACE inhibitors affect kininase II, resulting in in-
creased bradykinin levels [81. Recent studies suggest that brady-
kinin modulates nitric oxide (NO) synthesis in endothelium [91.A
potential role of NO in models of renal injury has not been clearly
established.
Specific nonpeptidic angiotensin II receptor antagonists (Ang II
receptor antagonists) devoid of agonistic effects have been devel-
oped [10—12]. Their effect in some experimental models of renal
disease has been examined. Tanaka et al treated rats with the
nephrotic syndrome due to puromycin with an ACE inhibitor or
an Ang II receptor antagonist, and reported that both agents
ameliorated glomerulosclerosis [13]. Pimentel et al administered
an ACE inhibitor or an Ang II receptor antagonist to rats before
UUO and showed that both drugs improved the hemodynamics of
the post-obstructed kidney and normalized eicosanoid excretion
[14].
It is well recognized that the renin-angiotensin system (RAS) is
up-regulated in the setting of UUO [2, 31 and that Ang II
stimulates the synthesis of transforming growth factor 131 (TGF-
131) in this model of kidney disease [15] and in vascular smooth
muscle [16]. We reported previously that TGF-p1 mRNA [15] and
collagen IV synthesis [17] were increased in the obstructed kidney
of rats with UUO and these changes were partially blunted by the
administration of the ACE inhibitor enalapril. It was of interest,
therefore, to elucidate whether an Ang II receptor antagonist
would have effects identical to those of an ACE inhibitor on
TGF-f31 and collagen IV mRNA synthesis and on the histological
changes of tubulointerstitial fibrosis.
This study examines the separate effects of an Ang II receptor
antagonist (SC-51316) and an ACE inhibitor (enalapril) on the
development of tubulointerstitial fibrosis in the kidney with UUO.
Methods
Experimental protocol
Female Sprague-Dawley rats, weighing 180 to 210 g, were used
in these experiments. Some animals underwent unilateral ureteral
obstruction (UUO): under pentobarbital anesthesia (5.0 mg/kg
body wt, i.p.) the left ureter was ligated with 4-0 silk at two points
and cut between the ligatures in order to prevent retrograde
urinary tract infection. Sham-operated (SO) rats had their ureters
manipulated but not ligated. These rats were used to obtain
"control" kidneys. Rats were sacrificed under pentobarbital anes-
thesia after five days of UUO or five days after SO.
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A nonpeptidic Ang II receptor antagonist, SC-51316 [18, 19]
(Searle, Skokie, IL, USA), was administered in the drinking water
(20 mg/liter) to UUO rats (N = 15) and SO rats (N = 5)beginning
24 hours before surgery and continuing through day 5 of ureteral
obstruction or through day 5 after sham operation. Two untreated
groups of rats (UUO, N = 12 and SO, N = 5) were administered
tap water alone instead of water containing SC-51316. An ACE
inhibitor, enalapril (200 mg/liter in the drinking water), was
administered to six rats with UUO.
Measurement of blood pressure and plasma renin activity
Blood pressure was measured after five days of UUO in
untreated and treated animals, as previously described [201.
Briefly, rats were lightly anesthetized with halothane. An indwell-
ing PE-50 catheter was placed into the left fenioral artery. After
30 minutes, for recovery from anesthesia and surgery, three
successive readings were obtained. Mean arterial pressure (MAP)
was determined on a continuous basis through the left femoral
artery catheter connected to an electronic transducer (Weco
VT-i, Winston Electronics, Millbrae, CA, USA) for an additional
10 minutes.
Heparinized plasma was obtained from each rat just before
sacrifice and stored at —70°C. Plasma renin activity was measured
using a commercial kit from DuPont (Boston, MA, USA).
Tissue preparation and RNA extraction
Rats were anesthetized with pentobarbital. For histological
studies the kidneys were perfused in vivo until clear of blood-
borne cells with cold Hank's balanced salt solution (HBSS), pH
7.2, and then with a tissue fixative (Histochoice, Amresco, Solon,
OH, USA) for 10 minutes. The kidneys were removed, sliced
axially in 3-mm thick sections, immersed in the same fixative for
four hours at 4°C, washed with HBSS and embedded in paraffin.
Paraffin sections, 4 jtM in thickness, were subjected to Azan-
Mallory staining or immunochemistry.
For RNA extraction kidneys were perfused in situ with cold
HBSS, removed quickly and placed in cold HBSS. The renal
cortex was dissected immediately, minced and washed twice with
cold HBSS, and then total RNA was extracted using the guani-
dinium isothiocyanate (RNAzol) method [21] (Cinna/Bioteck,
Houston, TX, USA). The total RNA was dissolved in RNAse-free
water (Sigma, St. Louis, MO, USA) and quantitated by UV
spectrophotometry at 260 nm and 280 nm. RNA with an OD26cJ
0D280 ratio greater than 1.9 was used for eDNA synthesis.
The deparaffinized sections were washed in 0.05 M Tris-HCI
buffer, pH 7.6, and incubated with 0.1% trypsin type I (Sigma) in
0.1% CaCI2 and 0.05 M Tris-HC1 buffer, pH 7.6 for 30 minutes at
room temperature. Sections were washed in phosphate buffered
saline (PBS) for 10 minutes three times, preincubated in blocking
solution (10% goat or rabbit serum in PBS) for 30 minutes,
washed in PBS three times and then incubated with primary
antibody in PBS for two hours at room temperature. Mouse
monoclonal antibody against monocytes/macrophages, ED-i
(1:2000 dilution; Harlan Bioproducts, Indianapolis, IN, USA),
PCNA (1:100 dilution) and aSMA (1:100 dilution; both from
Biogenex, San Ramon, CA, USA) and goat polyclonal antibody
against type IV collagen (1:40 dilution; Southern Biotechnology
Associates, Inc., Birmingham, AL, USA) were used as primary
antibodies. The serum of animals in which the primary antibody
was developed was used as a negative control. Each section was
washed three times in PBS and incubated with a second antibody
(1:500 dilution) in PBS for 30 minutes. Alkaline phosphatase
conjugated goat anti-mouse IgG, goat anti-mouse 1gM or rabbit
anti-goat IgG (Sigma) was used as a second antibody, all at 1:1000
dilutions. After washing with PBS three times, the section was
developed with Fast Red/Napthol.
Morphometric analysis of the interstitial volume, collagen IV or
zSMA matrix score, PCNA and monocyte/macrophage infiltration
For all morphologic evaluations the observer was naive to the
origin of the histologic sections. A standard point counting
method [22] was used to quantitate the volume of the renal
interstitium. The relative volume (Vv) of the renal cortical
interstitium was determined on sections using the Azan-Mallory
method to stain collagen fibers in tubular basement membrane
(TBM), glomeruli, and interstitial space. Under high magnifica-
tion (x400) consecutive non-overlapping fields were photo-
graphed from each section of renal cortex. A grid containing 117
(13 x 9) sampling points was superimposed on each photograph
and a total of 1,404 to 2,691 points were evaluated in each kidney.
The number of points overlying TBMs and interstitial space was
counted while points falling on Bowman's capsule or peritubular
capillaries were not. Points falling on glomerular structures or on
large vessels were excluded from the total count.
The matrix score for collagen IV or zSMA expression in the
renal cortical interstitium was determined as described previously
[17]. Twenty random, non-overlapping fields of sections stained
for either collagen IV or aSMA were assigned a score of zero to
three. A score of zero was assigned when the immunohistologic
appearance was equivalent to that of a normal or sham-operated
kidney. Progressively higher scores were assigned depending on
the degree and amount of interstitium that reacted with the
antibodies specific for collagen IV or aSMA. The scores of the
twenty fields of each kidney were averaged. The score of three
separate animals was then averaged.
Monocyte/macrophage infiltration was determined by the num-
ber of cells within the cortex which stained positively with the
ED-i antibody. As in the method described before [17], three
randomly chosen fields from the same section of the individual rat
renal cortex were photographed under 200 X magnification, and
the number of ED-i positive cells was calculated and averaged
(cells/200X field).
For visualizing PCNA within nuclei, deparaffinized sections
were immersed in 0.01 N hydrochloric acid for 10 minutes
followed by washing in PBS. This treatment enhances the reac-
tivity of the antibody with PCNA. The sections were then stained
as described above. For the PCNA studies kidney sections were
obtained from animals sacrificed after three days of UUO without
or with inhibitor treatment.
Characterization and quantification of TGF-131 and collagen
a(Jfr) mRNA by reverse transcription -polymerase chain reaction
First-strand eDNA primed with oligo dT was synthesized with a
cDNA cycle kit from Promega (Madison, WI, USA) using 2 tg of
total RNA for TGF-/31 and 4 g for collagen IV. The mixture of
total RNA and oligo dT primer was incubated at 65°C for 10
minutes to denature the secondary structure and chilled on ice.
The resulting mixture was incubated at 42°C for one hour, heated
to 94°C for five minutes and chilled on ice. A second round of
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Table 1. Mean arterial pressure and plasma renin activity of study
groups
Treatment
MAP
mm Hg N
PRA
ng/hr/ml N
Sham-untreated ND 4.3 0.8 4
UUO-untreated 124 2 3 8.4 0.5 6
UUO-SC-51316 124 1 3 58.6 4.8a 5
UUO-enalapril ND 69.0 49a 3
Values represent the mean SD. Abbreviations are: MAP, mean
arterial pressure; N, number of animals; PRA, plasma renin activity;
UUO, unilateral ureteral obstruction; ND, not determined in this study.
P < 0.0001 compared to UUO-untreated
Fig. 1. Effect of A CE inhibition or Ang II receptor antagonism on interstitial
volume of the kidney with an obstructed ureter. Symbols are: (PA) OBK; ()
CLK. The interstitial volume (Vv) of the kidney cortex of untreated,
enalapril treated or SC-51316 treated animals was determined as de-
scribed in the Methods. The difference in the Vv between the OBK of
enalapril and SC-51316 treated animals is significantly different from that
of the untreated animals. N = 6 for the untreated group; N = 8 for the
enalapril-treated group; N 6 for the SC-51316 treated group.
reverse transcription was performed after adding 5 units of avian
myeloblastosis virus (AMV) enzyme.
Polymerase chain reaction (PCR) was performed using 3 1.d of
each cDNA. Amplification was in a total volume of 50 pi
containing PCR buffer (50 mM KC1, 10 mrvt Tris-HC1), 1.5 mM
MgCI2, 200 jiM of each dNTP, 50 pmol of oligonucleotide primers
for TGF-131 or 100 pmol for collagen IV, and 1.25 units of Taq
DNA polymerase (Promega). To quantitate PCR products and to
confirm the integrity of the RNAs we coamplified a housekeeping
gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in
companion tubes. We used a small amount (1 p1) of cDNA from
the cortex with 25 pmol of primers to amplify the GAPDH
message. The TGF-pl primers were designed from the sequence
of the rat gene: 5'-AATACGTCAGACATTCGGGAAGCA
(sense) from exon 2 and 3'-GTCAATGTACAGCTGCCGTA-
CACA (antisense) from exon 6 to yield a 498 bp product [23]. The
collagen cd(IV) primers were designed from the mouse gene:
5'-GTGCGGTTTGTGAAGCACCG (sense) and 3'-GTTCT-
TCTCATGCACACTT (antisense) to yield a 363 bp product [24].
The GAPDH primers were designed from the rat gene: 5'-
AATGCATCCTGCACCACCAA (sense) and 3'-GTAGCCATA-
TTCATTGTCATA (antisense) to yield a 515 bp product [25].
PCR was performed with a Perkin Elmer Cetus DNA Thermal
Cycler using the following program: 94°C for one minute (dena-
turing), 60°C for one minute (annealing) (54°C with collagen IV
primers), and 72°C for two minutes (extension). Amplification was
carried out at 30 cycles with TGF-f3 primers, 40 cycles with
collagen IV primers and 28 cycles with GAPDH primers.
PCR products were quantitatively analyzed as described previ-
ously [17]. After amplification, 15 j.tl of each PCR reaction mix
was electrophoresed through a 1.2% agarose gel with ethidium
bromide (0.5 jig/ml). The gel was photographed with Polaroid
Type 665 positive/negative film (Polaroid Corporation, Cam-
bridge, MA, USA) over UV light at the same exposure and
developing time for all gels photographed. The bands on the
negative film were scanned by densitometry (Sepra Scan 2001
software, Integrated Separation System, Natwick, MA, USA) for
quantitation. The PCR products of TGF-f31 and GAPDH, or
collagen IV and GAPDH (those amplified from the same cDNA)
were electrophoresed in the same gel and the ratios TGF-f31/
GAPDH or collagen IV/GAPDH were determined to eliminate
gel to gel or film to film variance.
Statistical analysis
Data, shown as mean SD, were analyzed by the unpaired t-test
on the Macintosh StatView program. Comparisons between val-
ues for the contralateral (CLK) and obstructed kidneys (OBK)
were performed using a paired t-test. ANOVA was employed to
determine the significance of the relative volume of the renal
interstitium (Vv), ED-i cell infiltration, collagen IV or aSMA
matrix score, plasma renin activity and PCNA in nuclei.
Results
Morphometric analysis of interstitial volume
The relative volume of the cortical interstitium was expressed as
the volume fraction (Vv) (Fig. 1). UUO of five days duration
resulted in a significant increase (P < 0.0001, N = 6) in the Vv of
the OBK (38 5.9%) compared to the CLK (8.4 1.5%). The
Ang II receptor antagonist, SC-51316, significantly reduced Vv in
the OBK, to 21 4.9% (P < 0.001 compared to untreated OBK,
N = 6). This decrease in the Vv was almost identical to that
observed with enalapril previously [17] and again in this study in
a new group of rats (15.6 4.3%, N = 3; Fig. 1). No significant
difference was observed in the Vv of the CLK between untreated
rats and rats treated with SC-51316 or enalapril.
Blood pressure and plasma renin activity
Treatment with SC-5 1316 had no significant effect on the blood
pressure of rats with UUO (Table 1). This is in contrast to the 21
mm Hg average decrease (from 121 to 100 mm Hg) that we
previously found in rats with UUO treated with enalapril [17].
Plasma renin activity (PRA), however, was significantly greater in
rats with UUO treated with SC-51316 (58.6 4.8 ng/hr/ml vs. 8.4
0.5 ng/hr/ml in untreated rats with UUO). This is comparable
to the increase in PRA observed with enalapril treatment (Table
1).
Immunohistochemical studies on collagen IV and aSM4 protein
in the interstitium
Interstitial collagen IV was evident in the OBK after five days
of UUO as compared to the CLK of the same rats (Fig. 2).
Enalapril SC 51316
treated treated
40
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Untreated
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Fig. 2. Effect of ACE inhibition or Ang II receptor antagonism on collagen IV distribution within the kidney with an obstrwted ureter. Collagen IV
distribution was visualized by an immunocytochemical technique. Representative sections of kidney from contralateral untreated (A), obstructed-
untreated (B), obstructed-enalapril-treated (C) and obstructed SC-51316-treated (D) animals are shown.
Table 2. Matrix score for interstitial protein expression of collagen IV
and a smooth muscle antigen
Protein Treatment
Score Average
score0 1 2 3
Collagen IV None
Enalapril
SC.51316
03 2
0
0
25 10
20 13
18 858 863 8
81 813 3
17 6
2.81 0.08
1.85 0.13a
1.97 0.19
aSMA None
Enalapril
SC-51316
0
47 13
38 10
0
48 16
45 10
52 38 8
15 5
47 3
01 1
2.47 0.03
0.65 013h
0.80 018h
Values represent the mean SD of the average matrix score (average of
20 independent fields) of each of 3 separate obstructed kidneys. The
matrix scores of the contralateral kidney for each protein for each
treatment was zero (not shown).
P < 0.002; "P < 0.0001 compared to no treatment.
Collagen IV was observed in the TBM, Bowman's capsule, and
mesangium in the sham-operated (SO) (not shown) and contralat-
eral kidney (CLK) of control rats (Fig. 2A). The obstructed kidney
(OBK) showed an increased deposition of collagen IV protein,
especially in the renal interstitial space (Fig. 2B). There was a
greatly reduced deposition of collagen IV protein in the OBK
after five days of UUO in rats treated with the ACE inhibitor (Fig.
2C) and the angiotensin II receptor antagonist SC-5 1316 (Fig.
2D).
The protein tSMA is expressed in the renal mesangium in a
variety of glomerular diseases [26]. Previous studies had indicated
that an actin isoform was expressed in the kidney interstitium
during hydronephrosis [27]. The appearance of aSMA in the
widened interstitial space during UUO is illustrated in Figure 3 A
and B. In the CLK the aSMA was found only in blood vessels
(Fig. 3A). In the OBK there was a substantial amount of aSMA
within the increased cellularity of the interstitium (Fig. 3B) as well
as in the blood vessels. Administration of either enalapril (Fig.
3C) or SC-51316 (Fig. 3D) greatly decreased aSMA expression.
The ability of an ACE inhibitor and an Ang II receptor
antagonist to quantitatively decrease collagen IV and aSMA is
shown in Table 2. For collagen IV expression the untreated OBK
had an average matrix score of 2.81 0.08, which was significantly
reduced to 1.85 0.13 with enalapril or to 1.97 0.19 with
SC-51316 treatment. For aSMA expression the OBK matrix score
averaged 2.47 0.03 with no treatment and 0.65 0.13 and 0.80
0.18 with enalapril and SC-51316 treatment, respectively.
Monocytelmacrophage infiltration of the kidney during UUO
As reported previously [4], there is infiltration of the renal
cortex of the OBK by ED-i positive monocytes/macrophages
during UUO (Fig. 4 A and B). Unlike enalapril treatment (Fig.
4C), SC-51316 treatment did not reduce significantly the number
of ED-i positive cells in the OBK (Fig. 4D). There was little
infiltration by ED-i positive cells in the contralateral kidneys of
untreated rats with UUO (Fig. 4A), or rats with UUO receiving
SC-51316 or enalapril (not shown). Quantitatively, enalapril re-
duces ED-i positive cell infiltration from an average of 67.9 3.1
to 10.7 0.9 cells per field (P < 0.0001) (Fig. 5). There was no
decrease of ED-I positive cells in the cortex of the SC-51316
treated OBK, which remained at 63.2 10.9 cells per field.
Proliferating cell nuclear antigen (PCNA) expression during UUO
Previous studies reported an increased thymidine incorporation
into tubular and interstitial cell nuclei of kidneys with ureteral
obstruction [28]. Rather than using thymidine incorporation as an
indication of DNA synthesis we followed an immunocytochemical
approach based upon the expression of a DNA polynierase-
associated protein, PCNA [29, 30]. In preliminary studies we
determined that PCNA expression peaked at three days of UUO,
which is similar to the time course for thymidine incorporation
[28]. Both enalapril and SC-51316 significantly decreased the
number of PCNA positive nuclei in the OBK compared to no
treatment at all (Fig. 6). There is a decrease in PCNA expression
in nuclei of both tubular and interstitial cells (Fig. 7).
Expression of TGF-131 mRNA and collagen IV mRNA
during UUO
As we reported previously [15, 17], the OBK of untreated rats
with UUO showed a prominent increase of both TGF-f31 and
collagen IV mRNA levels as compared to the CLK. We used the
same technique [15, 17] to examine the effect of Ang II receptor
antagonism on the mRNA label of these factors associated with
tubulointerstitial fibrosis.
Treatment with SC-5i3i6 or enalapril clearly blunted the
increase in mRNA levels of both TGF-f31 and collagen IV in the
OBK. Figures 8 and 9 demonstrate the relative levels of mRNA
expression of TGF-j31 and collagen IV, respectively. The increase
in the mRNA level of TGF-f31 in the OBK above that in the CLK
was significantly lessened (75%) by SC-51316 (P < 0.0001) and by
enalapril (43%, P < 0.02). The increased amount of collagen IV
in the OBK was also diminished 41% by the receptor antagonist
and 45% by the converting enzyme inhibitor (each P < 0.05).
Neither the TGF-/31 mRNA nor the collagen IV mRNA level of
the CLK was affected by treatment with the ACE inhibitor or the
Ang II receptor antagonist.
Discussion
Angiotensin II has several biological effects in the kidney
including vasoconstriction, modulation of tubular reabsorption,
and stimulation of renal growth; it also serves as a chemoattrac-
tant [31]. Two different types of receptors for Mg II binding have
Fig. 3. Effect ofACE inhibition orAng II receptor antagonism on a smooth muscle actin distribution within the kidney with an obstructed ureter. Distribution
of a smooth muscle actin was visualized by an immunocytochemical technique. Representative sections of kidney from contralateral untreated (A),
obstructed-untreated (B), obstructed-enalapril-treated (C) and obstructed SC-51316-treated (D) animals are shown.
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Fig. 4. Effect of ACE inhibition orAng II receptor antagonism on ED-I cell distribution within the kidney with an obstructed ureter. ED-i cell distribution
was visualized by an immunocytochemical technique. Representative Sections of kidney from contralateral untreated (A), obstructed-untreated (B),
obstructed-enalapril-treated (C) and obstructed SC-51316-treated (D) animals are shown. N = 3 for the untreated group; N = 3 for the enalapril-treated
group; N = 5 for the SC-51316 treated group.
Untreated Enalapril
treated
Fig. 5. Effect of ACE inhibition or Ang Ii receptor antagonism on ED-I
(monocyte/macrophage) infiltration of the kidney with an obstructed ureter.
Symbols are: () OBK; () CLK. The ED-i positive cells of untreated,
enalapril treated or SC-5i316 treated animals were determined as de-
scribed in the Methods. The number of ED-i positive cells in the OBK of
enalapril treated animals is significantly different from that in the OBK of
untreated or SC-51316 treated animals. N = 3 for the untreated group; N
= 3 for the enalapril-treated group; N = 5 for the SC-513i6 treated group.
been described: Ang II type 1 receptor (AT1 receptor) and Aug II
type 2 receptor (AT2 receptor) [321. Recent studies have reported
the preponderance of AT1 receptors and their distribution in the
mammalian kidney. In the rat kidney AT1 receptors are abundant
in proximal tubules, the thick ascending limb of Henle and
glomeruli [33, 34]. The distribution of these receptors in the
kidney is consistent with the sites at which Ang II expresses its
biological effects.
Previously, Ang II peptidic antagonists, like saralasin, were
utilized to block the effects of Ang II in the kidney [35]. Recently,
nonpeptidic Ang II receptor antagonists such as SC-51316 [10],
losartan [11] or L158,809 [12] have been developed. Unlike
previous Ang II antagonists, these new agents have little agonistic
effect(s) and have lower IC50 values. The specific features of these
Ang H antagonists seem ideal for binding to the endogenous AT1
receptor and provide a tool to investigate the role of Ang II itself
in the progression of tubulointerstitial fibrosis.
We found that administration of enalapril ameliorated the
renal tubulointerstitial fibrosis that develops after ureteral ob-
struction [17]. However, it is possible that this effect may be in part
modulated or enhanced by the kinin-kallikrein system because
enalapril is an inhibitor of kininase II and may thus up-regulate
the levels and activity of kinins [36]. Increased levels of kinins may
play a role besides the decrease in the levels of Ang II in the
tubulointerstitial fibrosis of ureteral obstruction. In this study we
examined the potential role of endogenous Ang II per se in the
tubulointerstitial fibrosis that develops in the obstructed kidney by
administering a specific Ang II receptor antagonist, SC-51316, to
experimental animals.
We administered SC-5 1316 orally in the drinking water at a
dose of 20 mg/liter. This amounted to the consumption of 3 to 3.5
mg/kg/day. Our dosage did not alter systemic MAP but it was
sufficient to increase the level of PRA (Table 1). AT1 receptors
are abundant in renal tissue [31] and our dosage and method of
administration should have provided a sufficient amount of SC-
51316 to produce a biological effect.
Several groups have documented an expansion of the renal
interstitium due to chronic ureteral obstruction [3, 5, 17, 22, 37].
This expansion is due to several factors including but not limited
to an increase in matrix proteins [17, 37, fibroblast proliferation
[17, 27] and macrophage infiltration [4, 17, 38]. The relative
volume of the interstitium of the cortex in the OBK was signifi-
cantly reduced by treatment with either an Ang II receptor
antagonist or an ACE inhibitor.
By immunohistochemical techniques, we found that the in-
creased deposition of collagen IV and aSMA protein in the OBK
was attenuated by treatment with the Ang II receptor antagonist.
The magnitude of this effect was similar to that obtained with
enalapril treatment. However, the administration of the Ang II
receptor antagonist, unlike that of enalapril, did not reduce the
infiltration of the renal parenchyma of the obstructed kidney by
monocytes/macrophages (Figs, 3B and 4). This may be due to
differences in the intrarenal levels of Ang II between the two
treatment groups. There are several possible chemoattractants for
monocytes/macrophages that appear to operate sequentially or in
tandem during UUO. These include a lipid factor [39], monocyte
chemotactic protein I [38] and TGF-131 [40]. Although TGF-131
mRNA and presumably the protein are attenuated by enalapril or
the Ang II receptor antagonist, little is known concerning their
effects on the synthesis of other chemoattractants. It is possible
that such effects contribute to the decrease in monocyte/macro-
phage infiltration in the presence of an inhibitor of the ACE. A
kinin-mediated increase in nitric oxide [9], which can reduce the
adhesiveness of the monocytes, might also have a role [41]. These
possibilities await testing. Macrophages produce many biologi-
cally important cytokines and other products such as TGF-/31,
TNFa and inducible nitric oxide (iNOS). The density of infiltrat-
ing mononuclear cells in the renal interstitium correlates well with
declining renal function [42]. Our results showed a discrepancy
between the decrease in renal interstitial volume and an un-
changed number of ED-i positive cells infiltrating the renal
parenchyma with Ang II receptor blockade alone. This suggests
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Fig. 7. Effect of ACE inhibition or Ang II receptor antagonism on PCNA
positive nuclei of the kidney with an obstructed ureter. Symbols are: (•)
tubules; () interstitium. The PCNA positive nuclei of untreated, enala-
pril treated or SC-51316 treated animals were determined as described in
the Methods. The number of PCNA positive nuclei in both tubular and
interstitial cells in the OBK of enalapril treated animals is significantly
different from that in the OBK of untreated or SC-51316 treated animals.
N = 3 for all groups.
Fig. 8. Effect of ACE inhibition orAng II receptor antagonism on TGF-j31
mRNA levels of the kidney with an obstructed ureter. Symbols are: (VA)
OBK; () CLK. The TGF-/31 mRNA content of the OBK of enalapril
treated or SC-51316 treated animals is significantly different from that of
untreated animals. N = 6 for the untreated group; N = 3 for the enalapril
treated group; N = 9 for the SC-51316 treated group.
that while monocyte/macrophage infiltration persists in the pres-
ence of Ang II receptor blockade, subsequent deleterious effects
of these ED-i positive cells are apparently attenuated.
TGF-pi has pleiotropic effects on matrix protein production
including an increase in the mRNA of extracellular matrix (ECM)
components and an increase in plasminogen activator inhibitor-i
(PAl-i) that may inhibit the ECM degradation by plasmin and
metalloproteinases [40]. Our studies showed that the levels of
TGF-f31 mRNA and collagen IV mRNA are increased in the
cortex of OBK of rats with UUO compared with CLK of the same
rats or the kidney of normal rats (Figs. 8 and 9). Therefore, we
suggest that increased levels of TGF-131 in the cortex caused an
increase in the synthesis of collagen IV mRNA and subsequently
of collagen IV protein. This is a position that we [15] and others
Fig. 9. Effect of ACE inhibition orAng II receptor antagonism on collagen
IV mRNA levels of the kidney with an obstructed ureter. Symbols are: (P1)
OBK; () CLK. The collagen IV mRNA content of the OBK of enalapril
treated or SC-51316 treated animals is significantly different from that of
untreated animals. N = 6 for the untreated group; N = 3 for the
enalapril-treated group; N = 9 for the SC-51316 treated group.
[19] have advanced previously. During the five days of UUO the
CLK did not show any significant changes when compared to the
kidneys of normal rats. The Ang II receptor antagonist signifi-
cantly blunted the increase in the levels of both TGF-131 mRNA
and collagen IV mRNA in the OBK. These data suggest a
beneficial effect of the Ang II receptor antagonist in the develop-
ment of tubulointerstitial fibrosis as found in our morphological
studies. The Ang II receptor antagonist had no detectable effects
in the CLK of rats with UUO or the kidney of SO rats.
Both enalapril and the Ang II receptor antagonist significantly
decreased the number of tubular and interstitial cell nuclei that
stained positive for PCNA. The decrease in the interstitium could
be explained by an attenuation of cell proliferation, since Ang II
is mitogenic for fibroblasts [3i], or this could even involve
proliferation of infiltrating mononuclear cells. In this setting the
PCNA appears to be involved in cell proliferation. There are
numerous tubular cells which also have nuclei that stain positive
for PCNA. Realistically, some but not all of these tubular cells are
proliferating. The PCNA can, however, be associated with the
DNA repair process [43] as suggested by similar observations
made in the postischemic kidney [441. This implies that events
during ureteral obstruction that contribute to the need for DNA
repair are driven by Ang II. It is also possible that Ang II receptor
antagonism has prolonged the time required for eventual fibrosis
of the kidney rather than halting fibrosis outright. Enalapril and
SC-51316 appear to be equally effective in decreasing PCNA
expression in both the tubular and interstitial cell nuclei although
the molecular basis (that is, an inhibition of proliferation or an
alteration of the cell cycle) may well be different between the two
cell populations. TGF-f3i is usually associated with an inhibition
of cell proliferation [40]. Interestingly, there is a precipitous
decline of interstitial cell proliferation in the OBK between three
and five days of UUO [32, and data not shown]. This coincides
with the plateau of TGF-J31 mRNA expression in the OBK [i51.
The renin-angiotensin system is activated during ureteral ob-
struction. Increasing Ang II stimulates TGF-1 synthesis in
endothelial cells [40], and the increased levels of TGF-/31 in turn
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may result in the increase of collagen IV in the tubulointerstitium.
This study revealed that the Mg II receptor antagonist blunted
the increased TGF-/31 mRNA by about 75% and collagen IV
mRNA by roughly 45% and reduced the expansion of the
interstitial volume by about 45%. These results duplicate closely
those reported previously utilizing treatment with enalapril which
had been administered intraperitoneally [17]. In the present study
we compared SC-51316, 20 mg/liter versus enalapril, 200 mg/liter
in the drinking water. We could obtain effects with relatively low
doses of SC-51316, which did not affect blood pressure. Therefore,
this study provides strong evidence for an important role of the
renin-angiotensin system in the kidney in the pathogenesis of
tubulointerstitial fibrosis per se and tends to minimize effects due
to decreases in systemic blood pressure. The tubulointerstitial
fibrosis of obstructive nephropathy is mediated, at least in part, by
increased levels of Ang II in renal tissue.
In summary, this report demonstrates that the tubulointerstitial
fibrosis resulting from UUO was ameliorated by treatment with a
specific Mg II receptor antagonist, SC-5 1316. In UUO, mono-
cyte/macrophage infiltration of the kidney was evident and the
renal cortical interstitium was extremely expanded. Collagen type
IV (collagen IV) mRNA and protein synthesis may be activated
by TGF-131 and contribute in part to the expanded cortical
interstitium. Administration of an Ang II receptor antagonist
significantly reduced this expanded renal cortical interstitium and
blunted the increased expression of TGF-f31 mRNA and collagen
IV mRNA. Of interest was the fact the monocyte/macrophage
infiltration was not influenced by the Ang II receptor antagonist,
but paracrine effects, if any, that this infiltrate may have on fibrosis
seem to have been blunted by the receptor antagonist. These
beneficial effects are similar to those previously found in animals
treated with enalapril, an ACE inhibitor. Our study strongly
suggests that the major pathologic changes of tubulointerstitial
fibrosis in UUO appear to be driven by increased levels of Mg II.
No reprints of this article are available.
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